A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRα, and LXRβ

Pharmaceutical Research

Volumn 19, Issue 12, 2002, Pages 1788-1800

  Ekins, Sean ^a   Mirny, Leonid ^b   Schuetz, Erin G ^c  

^a 19034   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CAR; FXR; LXR; Pharmacophore; PXR

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANDROSTANE DERIVATIVE; BILE ACID; CALCITRIOL; CALCIUM CHANNEL AFFECTING AGENT; CELL NUCLEUS RECEPTOR; CHOLESTEROL DERIVATIVE; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DRUG; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; GUGGULSTERONE; HORMONE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERFORIN; LIGAND; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; NATURAL PRODUCT; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT;

AMINO ACID SEQUENCE; CALCULATION; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG TOXICITY; HUMAN; MODEL; MOLECULE; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; RELIABILITY; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; DNA-BINDING PROTEINS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION FACTORS;

EID: 0036909462     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021429105173     Document Type: Review

References (118)

1. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
2. R. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
3. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitiors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408-414 (1999).
4. E. G. Scheutz, W. T. Beck, and J. D. Scheutz. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:311-318 (1996).
5. E. G. Schuetz, A. H. Schinkel, M. V. Relling, and J. D. Schuetz. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93:4001-4005 (1996).
6. V. J. Wacher, C. Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:129-134 (1995).
7. M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283:1552-1562 (1997).
8. J. Grober, I. Zaghini, H. Fujii, S. A. Jones, S. A. Kliewer, T. M. Willson, T. Ono, and P. Besnard. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274:29749-29754 (1999).
9. M. Makishima, A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, M. V. Hull, K. D. Lustig, D. J. Mangelsdorf, and B. Shan. Identification of a nuclear receptor for bile acids. Science 284:1362-1365 (1999).
10. D. J. Parks, S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. A. Kliewer, J. B. Stimmel, T. M. Willson, A. M. Zavacki, D. D. Moore, and J. M. Lehmann. Bile acids: Natural ligands for an orphan nuclear receptor. Science 284:1365-1368 (1999).
11. E. Y. Zhang, M. A. Phelps, C. Cheng, S. Ekins, and P. W. Swaan. Modeling of active transport systems. Adv. Drug Deliv. Rev. 54:329-354 (2002).
12. A. R. Tall, N. Wang, and P. Mucksavage. Is it time to modify the reverse cholesterol transport model? J. Clin. Invest. 108:1273-1275 (2001).
13. D. W. Russell. Nuclear orphan receptors control cholesterol catabolism. Cell 97:539-542 (1999).
14. J. T. Moore and S. A. Kliewer. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10 (2000).
15. B. Blumberg and R. M. Evans. Orphan nuclear receptors - New ligands and new possibilities. Genes Dev. 12:3149-3155 (1998).
16. D. J. Waxman. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369:11-23 (1999).
17. W. Xie and R. M. Evans. Orphan nuclear receptors: The exotics of xenobiotics. J. Biol. Chem. 276:37739-37742 (2001).
18. P. A. Edwards, H. R. Kast, and A. M. Anisfeld. BAREing it all. The adoption of lxr and fxr and their roles in lipid homeostasis. J. Lipid Res. 43:2-12 (2002).
19. A. Chawla, J. J. Repa, R. M. Evans, and D. J. Manglesdorf. Nuclear receptors and lipid physiology: Opening the X-files. Science 294:1866-1870 (2001).
20. S. A. Kliewer, J. M. Lehmann, and T. M. Willson. Orphan nuclear receptors: Shifting endocrinology into reverse. Science 284:757-760 (1999).
21. S. A. Kliewer and T. M. Willson. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43:359-364 (2002).
22. Y. Zhang and D. J. Mangelsdorf. LuXuRies of lipid homeostasis. Mol. Intervent. 2:78-87 (2002).
23. S. Ekins, B. J. Ring, G. Bravi, J. H. Wikel, and S. A. Wrighton. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium. In O. F. Guner (ed.), Pharmacophore, Perception, Development, and Use in Drug Design, University International Line, San Diego, California, 2000, pp. 269-299.
24. S. Ekins, C. L. Waller, P. W. Swaan, G. Cruciani, S. A. Wrighton, and J. H. Wikel. Progress in predicting human ADME parameters in silico. J. Pharmcol. Toxicol. Methods 44:251-272 (2000).
25. S. A. Wrighton, E. G. Schuetz, K. E. Thummel, D. D. Shen, K. R. Korzekwa, and P. B. Watkins. The human CYP3A subfamily: Practical considerations. Drug Metab. Rev. 32:339-361 (2000).
26. S. Ekins, G. Bravi, J. H. Wikel, and S. A. Wrighton. Three dimensional quantitative structure activty relationship (3D-QSAR) analysis of CYP3A4 substrates. J. Pharmacol. Exp. Ther. 291:424-433 (1999).
27. S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, and S. A. Wrighton. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4. J. Pharmacol. Exp. Ther. 290:429-438 (1999).
28. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M. S. Boguski, and E. Schuetz. Sequence diversity in CYP3A promotors and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27:383-391 (2001).
29. F. Ruschitzka, P. J. Meier, M. Turina, T. F. Luscher, and G. Noll. Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-549 (2000).
30. S. C. Piscatelli, A. H. Burstein, D. Chaitt, R. M. Alfaro, and J. Falloon. Indinavir concentrations and St. John's wort. Lancet 355:547-548 (2000).
31. E. A. Rekka and P. N. Kourounakis. An approach to QSAR of 16-substituted pregnenolones as microsomal enzyme inducers. Eur. J. Drug Metab. Pharmacokinet. 21:7-11 (1996).
32. G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Backman, R. Ohlsson, H. Postlind, P. Blomquist, and A. Berkenstam. Identification of the human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA 95:12208-12213 (1998).
33. B. Blumberg, W. J. Sabbagh, H. Juguilon, J. J. Bolado, C. M. van Meter, E. S. Ong, and R. M. Evans. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:3195-3205 (1998).
34. S. A. Kliewer, J. T. Moore, L. Wade, J. L. Staudinger, M. A. Watson, S. A. Jones, D. D. McKee, B. B. Oliver, T. M. Willson, R. H. Zetterstrom, T. Perlmann, and J. M. Lehmann. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82 (1998).
35. T. W. Synold, I. Dussault, and B. M. Forman. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 7:584-590 (2001.).
36. E. Schuetz and S. Strom. Promiscuous regulator of xenobiotic removal. Nature Med. 7:536-537 (2001).
37. J. Zhang, P. Kuehl, E. D. Green, J. W. Touchman, P. B. Watkins, A. Daly, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, S. A. Wrighton, M. Hancock, R. B. Kim, S. Strom, K. Thummel, C. G. Russell, J. R. Hudson Jr., E. G. Schuetz, and M. S. Boguski. The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572 (2001).
38. B. M. Forman. Polymorphisms in promiscuous PXR: An explanation for interindividual differences in drug clearance? Pharmacogenetics 11:551-552 (2001).
39. J. L. Staudinger, B. Goodwin, S. A. Jones, D. Hawkins-Brown, K. I. Mackenzie, A. LaTour, Y. Liu, C. D. Klaassen, K. K. Brown, J. Reinhard, T. M. Willson, B. H. Koller, and S. A. Kliewer. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 98:3369-3374 (2001).
40. R. E. Watkins, G. B. Wisely, L. B. Moore, J. L. Collins, M. H. Lambert, S. P. Williams, T. M. Willson, S. A. Kliewer, and M. R. Redinbo. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 292:2329-2333 (2001).
41. W. Xie, J. L. Barwick, M. Downes, B. Blumberg, C. M. Simon, M. C. Nelson, B. A. Neuschwander-Tetri, E. M. Brunt, P. S. Guzelian, and R. M. Evans. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439 (2000).
42. J. Staudinger, Y. Liu, A. Madan, S. Habeebu, and C. D. Klaassen. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29:1467-1472 (2001).
43. W. El-Sankary, G. G. Gibson, A. Ayrton, and N. Plant. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos. 29:1499-1504 (2001).
44. J. M. Wentworth, M. Agostini, J. Love, J. W. Schwabe, and V. K. Chatterjee. St. John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol. 166:R11-R16 (2000).
45. L. B. Moore, B. Goodwin, S. A. Jones, G. B. Wisely, C. J. Serabijt-Singh, T. M. Willson, J. L. Collins, and S. A. Kliewer. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 97:7500-7502 (2000).
46. I. Dussault, M. Lin, K. Hollister, E. H. Wang, T. W. Synold, and B. M. Forman. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276:33309-33312 (2001).
47. L. Drocourt, J. M. Pascussi, E. Assenat, J. M. Fabre, P. Maurel, and M. J. Vilarem. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29:1325-1331 (2001).
48. L. B. Moore, D. J. Parks, S. A. Jones, R. K. Bledsoe, T. G. Consler, J. B. Stimmel, B. Goodwin, C. Liddle, S. G. Blanchard, T. M. Willson, J. L. Collins, and S. A. Kliewer. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:15122-15127 (2000).
49. A. Takeshita, N. Koibuchi, J. Oka, M. Taguchi, Y. Shishiba, and Y. Ozawa. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur. J. Endocrinol. 145:513-517 (2001).
50. H. Masuyama, H. Inoshita, Y. Hiramatsu, and T. Kudo. Ligands have various potential effects on the degradation of pregnane X receptor by proteasome. Endocrinology 143:55-61 (2002).
51. H. Masuyama, Y. Hiramatsu, M. Kunitomi, T. Kudo, and P. N. MacDonald. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate pregnane X receptor-mediated transcription. Mol. Endocrinol. 14:421-428 (2000).
52. S. Ekins and J. A. Erickson. A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 30:96-99 (2002).
53. S. A. Kliewer, J. T. Moore, L. Wade, J. L. Staudinger, M. A. Watson, S. A. Jones, D. D. McKee, B. B. Oliver, T. M. Willson, R. H. Zetterstrom, T. Perlmann, and J. M. Lehmann. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82 (1998).
54. J. M. Lehmann, D. D. McKee, M. A. Watson, T. M. Willson, J. T. Moore, and S. A. Kliewer. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1016-1023 (1998).
55. R. E. Watkins, S. M. Noble, and M. R. Redinbo. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Dev. 5:150-158 (2002).
56. S. Ekins, M. de Groot, and J. P. Jones. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. 29:936-944 (2001).
57. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Application of three dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61:974-981 (2002).
58. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Three dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61:964-973 (2002).
59. K. R. Korzekwa, N. Krishnamachary, M. Shou, A. Ogai, R. A. Parise, A. E. Rettie, and F. J. Gonzalez. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147 (1998).
60. S. Ekins. B. J. Ring, S. N. Binkley, S. D. Hall, and S. A. Wrighton. Autoactivation and activation of cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 36:642-651 (1998).
61. C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:624-632 (2000).
62. S. Ekins and S. A. Wrighton. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:719-754 (1999).
63. B. Goodwin, L. B. Moore, C. M. Stoltz, D. D. McKee, and S. A. Kliewer. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60:427-431 (2001).
64. B. E. Daikh, J. M. Lasker, J. L. Raucy, and D. R. Koop. Regioand stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271:1427-1433 (1994).
65. A. Geick, M. Eichelbaum, and O. Burk. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-14587 (2001).
66. H. M. Kauffmann, S. Pfannschmidt, H. Zoller, A. Benz, B. Vorderstemann, J. I. Webster, and D. Schrenk. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 171:137-146 (2002).
67. A. Toell, K. D. Kroncke, H. Kleinert, and C. Carlberg. Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands. J. Cell. Biochem. 85:72-82 (2002).
68. S. A. Jones, L. B. Moore, J. L. Shenk, G. B. Wisely, G. A. Hamilton, D. D. McKee, N. C. Tomkinson, E. L. LeCluyse, M. H. Lambert, T. M. Willson, S. A. Kliewer, and J. T. Moore. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27-39 (2000).
69. G. I. Murray, W. T. Melvin, W. F. Greenlee, and M. D. Burke. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 41:297-316 (2001).
70. I. Stoilov. Cytochrome P450s: Coupling development and environment. Trends Genet. 17:629-632 (2001).
71. B. M. Forman, I. Tzameli, H. S. Choi, J. Chen, D. Simha, W. Seol, R. M. Evans, and D. D. Moore. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395:612-615 (1998).
72. D. Picard. Two orphans find a home. Nature 395:543-544 (1998).
73. I. Zelko and M. Negishi. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem. Biophys. Res. Commun. 277:1-6 (2000).
74. T. Sueyoshi, T. Kawamato, I. Zelko, P. Honkakoski, and M. Negishi. The repressed nuclear receptor CAR responds to phenobarbital in activating the Human CYP2B6 gene. J. Biol. Chem. 274:6043-6046 (1999).
75. P. Honkakoski, I. Jaaskelainen, M. Kortelahti, and A. Urtti. A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR). Pharm. Res. 18:146-150 (2001).
76. P. Wei, J. Zhang, M. Egan-Hafley, S. Liang, and D. D. Moore. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407:920-923 (2000).
77. E. L. LeCluyse. Pregnane X receptor: Molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. 134:283-289 (2001).
78. I. Tzameli and D. D. Moore. Role reversal: New insights from new ligands for the xenobiotic receptor CAR. Trends Endocrinol. Metab. 12:7-10 (2001).
79. P. Honkakoski, I. Zelko, T. Sueyoshi, and M. Negishi. The nuclear orphan receptor CAR-retinoid x receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell Biol. 18:5652-5658 (1998).
80. S. Ekins, G. Bravi, B. J. Ring, T. A. Gillespie, J. S. Gillespie, M. VandenBranden, S. A. Wrighton, and J. H. Wikel. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J. Pharmacol. Exp. Ther. 288:21-29 (1999).
81. S. Ekins and E. Schuetz. The PXR crystal structure: The end of the beginning. Trends Pharmacol. Sci. 23:49-50 (2002).
82. J. M. Pascussi, L. Drocourt, J. M. Fabre, P. Maurel, and M. J. Vilarem. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol. 58:361-372 (2000).
83. J. M. Pascussi, S. Gerbal-Chaloin, J. M. Fabre, P. Maurel, and M. J. Vilarem. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation. Mol. Pharmacol. 58:14411450 (2000).
84. J. M. Pascussi, L. Drocourt, S. Gerbal-Chaloin, J. M. Fabre, P. Maurel, and M. J. Vilarem. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem. 268:6346-6358 (2001).
85. W. Xie, J. L. Barwick, C. D. Simon, A. M. Pierce, S. Safe, B. Blumberg, P. S. Guzelian, and R. M. Evans. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/ PXR and CAR. Genes Dev. 14:3014-3023 (2000).
86. P. W. Swaan, F. C. J. Szoka, and S. Oie. Molecular modeling of the intestinal bile acid carrier: A comparative molecular field analysis study. J. Comput. Aided Mol. Des. 11:581-588 (1997).
87. K. H. Baringhaus, H. Matter, S. Stenglin, and W. Kramer. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter. J. Lipid Res. 40:2158-2168 (1999).
88. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D. J. Mangelsdorf, and F. J. Suchy. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276:28857-28865 (2001).
89. E. G. Schuetz, S. Strom, K. Yasuda, V. Lecureur, M. Assem, C. Brimer, J. Lamba, R. B. Kim, V. Ramachandran, B. J. Komoroski, R. Venkataramanan, H. Cai, C. J. Sinai, F. J. Gonzalez, and J. D. Schuetz. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytcochrome P450. J. Biol. Chem. 276:39411-39418 (2001).
90. R. B. Kim, B. Leake, M. Cvetkovic, M. M. Roden, J. Nadeau, A. Walubo, and G. R. Wilkinson. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J. Pharmacol. Exp. Ther. 291:1204-1209 (1999).
91. N. L. Urizar, A. B. Liverman, D. T. Dodds, F. V. Silva, P. Ordentlich,Y. Yan, F. J. Gonzalez, R. A. Heyman, D. J. Mangelsdorf, and D. D. Moore. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296:1703-1706 (2002).
92. P. J. Willy, K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. Mangelsdorf. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9:1033-1045 (1995).
93. B. A. Janowski, P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383:728-731 (1996).
94. J. M. Lehmann, S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J. L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and T. M. Willson. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:3137-3140 (1997).
95. X. Fu, J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow and E. G. Lund. 27-Hydroxycholesterol is an endogenous ligand for the liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276:38378-38387 (2001).
96. B. A. Janowski, M. J. Grogan, S. A. Jones, G. B. Wisely, S. A. Kliewer, E. J. Corey, and D. J. Mangelsdorf. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 96:266-271 (1999).
97. T. A. Spencer, D. Li, J. S. Russel, J. L. Collins, R. K. Bledsoe, T. G. Consler, L. B. Moore, C. M. Galaradi, D. D. McKee, J. T. Moore, M. A. Watson, D. J. Parks, M. H. Lambert, and T. M. Willson. Pharmacophore analysis of the nuclear oxysterol receptor LXRα. J. Med. Chem. 44:886-897 (2001).
98. J. L. Collins, A. M. Fivush, M. A. Watson, C. M. Galardi, C. L. Michael, L. B. Moore, D. J. Parks, J. G. Wilson, T. K. Tippin, J. G. Binz, K. D. Plunkett, D. G. Morgan, E. J. Beaudet, K. D. Whitney, S. A. Kliewer, and T. M. Willson. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45:1963-1966 (2002).
99. J. J. Repa, S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289:1524-1529 (2000).
100. P. Costet, Y. Luo, N. Wang, and A. R. Tall. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275:28240-28245 (2000).
101. M. A. Kennedy, A. Venkateswaran, P. T. Tarr, I. Xenarios, J. Kudo, H. N. Shimizu, and P. A. Edwards. Characterization of the human ABCG1 gene: Liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276:39438-39447 (2001).
102. A. Venkateswaran, J. J. Repa, J. M. Lobaccaro, A. Bronson, D. J. Mangelsdorf, and P. A. Edwards. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275:14700-14707 (2000).
103. K. E. Berge, H. Tian, G. A. Graf, L. Yu, N. V. Grishin, J. Schultz, P. Kwiterovich, B. Shan, R. Barnes, and H. H. Hobbs. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-1775 (2000).
104. J. J. Repa, K. E. Berge, C. Pomajke, J. A. Richarardson, H. Hobbs, and D. J. Mangelsdorf. Regulation of ATP-binding cassette sterol transporters, ABCG5 and ABCG8, by the oxysterol receptors. J. Biol. Chem. (2002).
105. H. R. Kast, B. Goodwin, P. T. Tarr, S. A. Jones, A. M. Anisfeld, C. M. Stoltz, P. Tontonoz, S. Kliewer, T. M. Willson, and P. A. Edwards. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277:2908-2915 (2002).
106. H. H. Bock and F. Lammert. Nuclear xeno-sensors as receptors for cholestatic bile acids: The second line of defense. Hepatology 35:232-234 (2002).
107. M. Makishima, T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, and D. J. Manglesdorf. Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313-1316 (2002).
108. L. Drocourt, J. C. Ourlin, J. M. Pascussi, P. Maurel, and M. J. Vilarem. Expression of CYP3A4, CYP2B6 and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. (2002).
109. K. Yamamoto, H. Masuno, M. Choi, K. Nakashima, T. Taga, H. Ooizumi, K. Umesono, W. Sicinska, J. VanHooke, H. F. DeLuca, and S. Yamada. Three dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain. Proc. Natl. Acad. Sci. USA 97:1467-1472 (2000).
110. G. Tocchini-Valenti, N. Roche, J. M. Wurtz, A. Mitschler, and D. Moras. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. USA 98:5491-5496 (2001).
111. R. E. Ostlund Jr., S. B. Racette, A. Okeke, and W. F. Stenson. Phytosterols that are naturally present in commercial corn oil significantly reduce cholesterol absorption in humans. Am. J. Clin. Nutr. 75:1000-1004 (2002).
112. R. Kaaks. Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 7:605-625 (1996).
113. Y. M. Mu, T. Yanase, Y. Nishi, N. Waseda, T. Oda, A. Tanaka, R. Takayanagi, and H. Nawata. Insulin sensitizer, troglitazone, directly inhibits aromatase in human ovarian granulosa cells. Biochem. Biophys. Res. Commun. 271:710-713 (2000).
114. S. Ekins, B. Boulanger, P. W. Swaan, and M. A. Z. Hupcey. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Computer Aided Mol. Des. (in press).
115. N. P. Brown, C. Leroy, and C. Sander. MView: A web-compatible database search or multiple alignment viewer. Bioinformatics 14:380-381 (1998).
116. D. G. Higgins, J. D. Thompson, and T. J. Gibson. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266:383-402 (1996).
117. J. D. Retief. Phylogenetic analysis using PHYLIP. Methods Mol. Biol. 132:243-258 (2000).
118. T. Schwede, A. Diemand, N. Guex, and M. C. Peitsch. Protein structure computing in the genomic era. Res. Microbiol. 151:107-112 (2000).